Media Coverage

Primary aldosteronism (PA) is a serious condition that affects as many as 5 to 10 percent of adults with high blood pressure (BP). High BP is widely prevalent in the U.S., nearly half of all adults (almost 120 million individuals) have it. Yet, for many years, PA was considered uncommon. However, recent research shows PA is both prevalent and under-detected. Untreated, it significantly raises risk of heart attack, stroke, and kidney disease.

Alzheimer’s disease (AD) is the major cause of dementia worldwide that leads to morbidity, long term care utilization, and significant healthcare costs. Dr. Yonghong Li and his colleagues at Quest Diagnostics performed a study to determine the efficacy and cost-effectiveness of using blood-based biomarker as a triage in Alzheimer’s disease testing. Dr. Michael K. Racke, Medical Director of Neurology at Quest Diagnostics and a co-investigator of this study summarized their findings.

Early cancer detection once meant imaging, pathology, and a defined set of screening tests with established follow-up pathways. Today, circulating tumor DNA assays, minimal residual disease (MRD) testing, and multi-cancer early detection platforms are expanding what is possible, often faster than the health systems meant to operationalize them.Yuri Fesko, MD, Senior Vice President and Chief Medical Officer for Quest Diagnostics, sees both extraordinary promise and practical disconnect.

In this episode of the WHOOP Podcast, WHOOP Founder and CEO Will Ahmed sits down with Quest Diagnostics CEO Jim Davis to discuss the partnership behind WHOOP Advanced Labs. Will and Jim discuss how combining blood biomarkers with continuous physiological data is reshaping consumer health.

City of Hope is implementing the Haystack minimal residual disease (MRD) test from Quest Diagnostics for clinical trial participants with solid tumor cancers. The research aims to guide disease management for patients with breast, colorectal, ovarian, and prostate cancer.

Quest Diagnostics on Tuesday raised its forecast for 2026 profit and revenue after posting first-quarter results above Wall Street estimates, citing resilient demand for routine diagnostic testing. Shares of the ​New Jersey-based company were up about 4% in early trading.

A blood test based from a South Baltimore lab is making treatment clearer for cancer patients. HaystackMRD, made by Haystack Oncology within Quest Diagnostics, looks for signs of cancer that conventional methods may miss. While it's been in development for many, many years, the test was made clinically available for oncologists and pharmaceutical partners in late 2024.

In this exclusive interview, Quest Diagnostics’ Ines Dahne-Steuber discusses their daytime kidney care lab strategy with MLO Editor in Chief, Christina Wichmann.

Per- and polyfluorinated alkyl substances, or PFAS, are known by many as “forever chemicals” due to the way they can accumulate and linger in the environment and body. These chemicals are widely used in thousands of industrial and consumer products and may enter the body through contaminated food and water. Research by Quest Diagnostics outlined similar results: men that were tested using the company’s PFAS blood test had higher PFAS concentrations in their blood than women who were tested.

Helio Genomics and Quest Diagnostics have partnered to expand access to a blood-based liver cancer test across the U.S. Starting in April, providers with a Quest account will be able to order HelioLiver, a test designed for early detection of hepatocellular carcinoma, through Quest’s network, according to a March 18 news release shared with Becker’s.